Feedback PLC Distribution agreement with GE Healthcare
25 April 2018 - 8:01AM
RNS Non-Regulatory
TIDMFDBK
Feedback PLC
25 April 2018
25 April 2018
Feedback plc
("Feedback" or the "Company")
Distribution agreement with GE Healthcare
Cambridge, UK - 25 April 2018: Feedback plc ("Feedback" or the
"Company") (AIM: FDBK), the specialist medical imaging technology
company, announces a software licence and distribution agreement
with General Electric Healthcare (GEHC) for TexRAD(R) ; the
Company's patented quantitative image texture analysis technology
for diagnostic radiological scans.
Feedback's subsidiary company, Feedback Medical Limited
(formally Cambridge Computed Imaging Ltd) has entered an agreement
with GEHC including GEHC Affiliates worldwide. The agreement grants
non-exclusive global rights for GEHC to offer TexRAD texture
analysis software for medical imaging research applications.
The structure of the agreement is designed to allow flexibility
within local markets to ensure that customer needs are met,
enabling GEHC to tailor the TexRAD research software to fulfil
requests for equipment, software and services. India will be the
first market where TexRAD will be offered under this agreement by
Wipro - GE Healthcare India. The relationship with India has been
founded by business development activities led by Dr Balaji
Ganeshan (Director of New Business, Feedback) with participation at
key conferences/meetings and healthcare trade mission by supported
by UK Department of International Trade. These led to detailed
discussions over the last year with GEHC about developing market
opportunities leading to the successful completion of the
Agreement.
TexRAD Research is currently installed in over 40 of the world's
leading research institutions across Europe, North America, Asia
and Australasia. The development of sales and customer engagement
in India via GEHC will build on the strong foundations of
Feedback's existing customer base. Feedback will also be working
with GEHC affiliates to identify further territories where TexRAD
can enhance the GEHC portfolio.
David Crabb, Chief Executive Officer of Feedback plc, said: "We
are delighted to be working with GE Healthcare as a major provider
of medical imaging equipment and services in India, demonstrated by
their commitment and investment in this market. This global
distribution agreement will further our international expansion,
ensuring that our technology continues to be used by the world's
leading institutions to expedite research in this important
field."
Ian McLellan, Commercial Director at CCI, added: "The
development of this agreement allows both parties to better respond
to local customer needs and enhance awareness of TexRAD to enhance
medical imaging research. We are pleased to be further supporting
the rapidly developing imaging expertise and healthcare provision
within India."
Notes to editors
About TexRAD(R) technology
TexRAD is the Company's patented quantitative image texture
analysis technology for diagnostic radiological scans. The
technology has the potential to assist clinicians in diagnosis,
prognosis and treatment of patients with cancer, or other disease
indications, and is currently installed in over 40 of the world's
leading research institutions across Europe, North America, Asia
and Australasia. By analysing the texture features in computerised
tomography (CT) scans, magnetic resonance images (MRI) and positron
emission tomography scans (PET/CT), TexRAD's quantitative imaging
capabilities provide clinicians with additional, visually
imperceptible information to make better decisions in order to
improve patient outcomes.
TexRAD research to date has shown great potential in many
different oncological and non-oncological sites. For example,
papers presented at RSNA 2017 focused on liver, pancreatic, kidney,
cervical, oral, genitourinary, head & neck, thyroid,
neuroendocrine and endometrial cancers, as well as gastrointestinal
stromal tumours, gliomas, thymic-epithelial neoplasms and
carotid-plaques. On 20 November 2017, Feedback announced the CE
marked release of TexRAD Lung, a "software only" Class 1 medical
device, to help advance lung cancer diagnosis. Further information
on the TexRAD technology can be found at www.texrad.com.
About Feedback plc
Feedback plc is a specialist medical imaging technology company.
It develops software and systems that provide innovative techniques
and improved workflows for practitioners involved in medical
research and treating patients. TexRAD(R) , the Company's patented
quantitative image texture analysis technology, has the potential
to assist clinicians in diagnosis, prognosis and treatment of
patients with cancer and is currently installed in over 40 of the
world's leading research institutions across Europe, North America,
Asia and Australasia. The Cadran platform provides a suite of
medical imaging tools for decision support. The Cadran range
includes the picture archiving communication system (PACS) to
provide decision support for scan analysis, diagnostic workstations
which provide secure remote access to view scans on demand, and
products to securely share and transport patient data. Visit
www.fbk.com.
For further information, please contact:
Feedback plc Tel: 01954 718072
David Crabb, Chief Executive Officer IR@fbk.com
Lara Mott, Investor Relations
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRASEMEELFASEDL
(END) Dow Jones Newswires
April 25, 2018 02:01 ET (06:01 GMT)
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jul 2023 bis Jul 2024